Telix Pharmaceuticals: Submits clinical briefing package to U.S FDA
- Telix Pharmaceuticals has submitted a clinical briefing package to the U.S FDA for its prostate cancer treating drug
- This comes after procedural guidance received from its pre-NDA meeting
- The company has also completed the additional manufacturing and product release analytics that recommended by the FDA
- Then the new drug targets cell surface prostate-specific antigen that over-expressed on most prostate cancer cells
- Current treatments also include palliative care, radiation therapy, prostatectomy and chemotherapy
- Telix is currently down a 2.80 per cent with shares trading for $1.57 apiece